Tesamorelin / MOTS-c

What is Tesamorelin / MOTS-c?

The Tesamorelin/MOTS-c combination is dispensed as a single compounded injection — both peptides formulated together by a licensed 503A compounding pharmacy and prescribed specifically for you. This means one injection delivers the full benefit of both peptides, rather than requiring separate administrations.

Tesamorelin works through the growth hormone axis: it stimulates the pituitary to release GH, which drives lipolysis (fat breakdown) in visceral adipose tissue — the metabolically harmful fat stored around the abdominal organs. It also improves lipid profiles, supports lean mass preservation, and has demonstrated cognitive benefits in clinical trials.

MOTS-c works at the mitochondrial level: it activates AMPK (the master metabolic regulator), improves insulin sensitivity in skeletal muscle and adipose tissue, promotes mitochondrial biogenesis, and regulates the folate cycle. Together in a single compounded formulation, Tesamorelin and MOTS-c address metabolic health from the top down (GH axis) and the bottom up (mitochondrial signaling) — a protocol that is particularly powerful for individuals with visceral adiposity, insulin resistance, or metabolic syndrome.

Top-down and bottom-up metabolic optimization

GH-Mediated Visceral Fat Reduction (Tesamorelin)

Tesamorelin stimulates pituitary GH release, which drives lipolysis in visceral adipose tissue — producing clinically significant reductions in abdominal fat with consistent use.

Mitochondrial AMPK Activation (MOTS-c)

MOTS-c activates AMPK — the master metabolic switch — promoting glucose uptake, fatty acid oxidation, and mitochondrial biogenesis at the cellular level.

Dual Insulin Sensitivity Improvement

Both peptides independently improve insulin sensitivity through different mechanisms — Tesamorelin through GH/IGF-1 effects on glucose metabolism, MOTS-c through direct AMPK-mediated insulin signaling enhancement.

Complementary Fat Metabolism

Tesamorelin preferentially targets visceral fat through GH-mediated lipolysis, while MOTS-c enhances overall fatty acid oxidation and metabolic efficiency — together addressing both the location and the rate of fat metabolism.

Cognitive & Energy Benefits

Tesamorelin's IGF-1 elevation supports cognitive function, while MOTS-c's mitochondrial activation improves cellular energy production — together supporting both mental and physical performance.

What patients report

—

Significant visceral fat reduction (Tesamorelin)

—

Improved insulin sensitivity and glucose metabolism (MOTS-c)

—

Enhanced mitochondrial function and cellular energy

—

Improved body composition — reduced fat, preserved lean mass

—

Better lipid profile — triglycerides, HDL

—

Cognitive function support

—

Improved exercise capacity and recovery

—

Comprehensive metabolic syndrome support

—

Synergistic effects greater than either peptide alone

Who is this combination protocol for?

—

Individuals with significant visceral adiposity and metabolic syndrome

—

Those with insulin resistance or pre-diabetes seeking comprehensive metabolic support

—

Adults seeking body composition improvement beyond what lifestyle changes alone can achieve

—

Patients in our Advanced Peptide or Longevity & Performance programs

—

Individuals with elevated cardiovascular risk factors related to metabolic health

—

Those who have tried individual metabolic peptides and want enhanced results

—

Health-conscious adults seeking comprehensive metabolic optimization as part of a longevity protocol

Frequently asked questions

Why combine Tesamorelin and MOTS-c rather than using them separately?

Tesamorelin and MOTS-c address metabolic health through complementary, non-overlapping mechanisms. Tesamorelin works through the GH axis to reduce visceral fat, while MOTS-c works at the mitochondrial level to improve insulin sensitivity and cellular energy metabolism. Compounding them into a single injection delivers synergistic benefits in one administration — particularly effective for individuals with both visceral adiposity and insulin resistance, where addressing only one pathway leaves the other untreated.

Is this combination appropriate for people with diabetes?

Both peptides can affect glucose metabolism and require careful monitoring in individuals with diabetes. Tesamorelin can transiently increase blood glucose through GH effects, while MOTS-c improves insulin sensitivity. The net effect depends on the individual. Your clinician will assess your metabolic health profile, current medications, and glucose control before prescribing and will monitor closely during treatment.

How does this compare to GLP-1 medications like Semaglutide?

GLP-1 medications (Semaglutide, Tirzepatide) work through appetite suppression and incretin effects to produce weight loss. Tesamorelin/MOTS-c works through GH stimulation and mitochondrial activation — mechanisms that are distinct from and complementary to GLP-1 pathways. Some patients use both approaches simultaneously under clinical supervision for comprehensive metabolic support.

How long before I see results?

Energy and metabolic improvements from MOTS-c are often reported within 4–6 weeks. Tesamorelin's effects on body composition typically become measurable at 8–12 weeks, with the most significant visceral fat reduction occurring between 3–6 months. Both peptides produce cumulative benefits with consistent use.

Can I add other peptides to this protocol?

Yes. The Tesamorelin/MOTS-c combination can be expanded with other peptides based on your goals. Common additions include Ipamorelin/CJC-1295 for enhanced GH stimulation, Thymosin Alpha-1 for immune support, or Semax/Selank for cognitive performance. Your clinician will design a comprehensive protocol that addresses your full range of longevity and performance goals.

Our services